- Revive Therapeutics (RVV) will be one of 17 companies included in the first psychedelics ETF (exchange traded fund)
- The ETF will be comprised of companies in Canada and the United States and will be managed by Horizons ETF Management
- The ETF is expected to start trading on January 26 under the ticker PSYC on the NEO exchange
- Revive focuses on research and development of therapeutics for medical needs and rare disorders
- Shares of Revive Therapeutics are up 4.68 per cent on the day, trading at C$0.45 at 1:39 p.m. EST
Revive Therapeutics (RVV) will be one of 17 companies included in the first psychedelics ETF (exchange traded fund).
The ETF will be comprised of companies in Canada and the United States and will be managed by Horizons ETF Management.
The Horizons psychedelic stock ETF index is expected to start trading on Tuesday, January 26, under the ticker PSYK on the NEO exchange.
Toronto-based Revive is a specialty life sciences company is focused on the research and development of therapeutics for medical needs and rare disorders.
“We are pleased to be included in the First Psychedelics ETF and being recognized as a leading company in the field of psychedelic pharmaceuticals,” said Revive CEO Michael Frank.
We are advancing novel psilocybin-based therapeutics using a proprietary oral thin film delivery technology and a natural biosynthesis enzymatic platform to support clinical research in mental health and substance abuse disorders.”
Revive is advancing its psychedelic pharmaceuticals pipeline with a focus on proprietary psilocybin-based therapeutics that includes the development of an oral thin film product in collaboration with the University of Wisconsin-Madison, a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform.
It is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Paediatric Disease designations.
Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted an orphan drug status designation by the FDA for the use of Cannabidiol (CBD) to treat autoimmune hepatitis.
Shares of Revive Therapeutics are up 4.68 per cent on the day, trading at C$0.45 at 1:39 p.m. EST.
